Impact of Weight Loss Following Bariatric Surgery on Pulmonary Function in Patients With Morbid Obesity
Increase in body mass index (BMI)is associated with a decrease in expiratory flows.Obesity is also associated with an increased prevalence of asthma.Consequences of obesity on respiratory function and on bronchial responsiveness are still to be documented.
This study aims to evaluate, before and after surgery, the impact of a bariatric surgery (biliopancreatic diversion with duodenal switch)on respiratory function in patients with morbid obesity .
Our hypothesis is that weight loss following bariatric surgery will induce significant improvements in pulmonary function and airway responsiveness, and, as a consequence, a reduction in respiratory symptoms,these changes being correlated with a reduction in systemic markers of inflammation. Maintenance of weight loss after one year will permit the persistence of these improvements
|Bariatric Surgery Obesity Respiratory Diseases|
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Impact of Weight Loss Following Bariatric Surgery on Pulmonary Function in Patients With Morbid Obesity|
|Study Start Date:||April 2006|
|Study Completion Date:||May 2011|
|Primary Completion Date:||January 2011 (Final data collection date for primary outcome measure)|
patients with morbid obesity undergoing a bariatric surgery
No bariatric surgery
patients with morbid obesity on a waiting list for a bariatric surgery but who will have their surgery in more than one year.
Patients will be evaluated before the surgery (time zero), 6 months and one year after their surgery. A control group of patients on a waiting list for bariatric surgery will be evaluated at time zero and after 6 months and one year.
At each visit,patients will:
- fill a standardized respiratory questionnaire and a questionnaire on sleep apnea; questionnaires on asthma control will be completed by patients with asthma.
- have a spirometry, pulmonary volumes measures by body plethysmography and methacholine inhalation test with evaluation of symptoms perception.
- an induced sputum will be performed.
- A blood sample will be drawn to evaluate inflammation and measure C-reactive protein concentration in plasma.
- An allergy skin prick test will be done at time zero.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00532896
|Centre de Recherche, Hôpital Laval|
|Québec, Quebec, Canada, G1V 4G5|
|Principal Investigator:||Louis-Philippe Boulet, MD||Hôpital Laval|